Analyst: Specialty Generic Markups Flagged by FTC Are ‘Growing Profit Pool for PBMs’
-
Jan 23, 2025
In a move endorsed by its new chairman, the Federal Trade Commission (FTC) on Jan. 14 issued its second interim staff report on PBMs, this time finding that the country’s three largest firms significantly marked up specialty generic drugs dispensed by their affiliated pharmacies.
The PBM industry’s main trade group, the Pharmaceutical Care Management Association (PCMA), says the FTC’s report is making “sweeping assertions about the role of PBMs disconnected from a full appreciation of their critical cost-saving role for employers, unions, taxpayers, and patients.”
Yet one equities analyst who focuses on the health care industry recently suggested to investors that the FTC may very well be onto something.
Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.